Bilateral Renal Metastasis of Hürthle Cell Thyroid Cancer with Discordant Uptake Between I-131 Sodium Iodide and F-18 FDG
10.1007/s13139-016-0462-5
- Author:
Apichaya CLAIMON
1
;
Minseok SUH
;
Gi Jeong CHEON
;
Dong Soo LEE
;
E Edmund KIM
;
June Key CHUNG
Author Information
1. Department of Nuclear Medicine, Seoul National University Hospital, 101 Daehangno, Jongro-gu, Seoul 110-744, Korea. larrycheon@gmail.com
- Publication Type:Case Report
- Keywords:
F-18 FDGPET/CT;
Hürthle cell thyroid cancer;
I-131 whole-body scan;
Renalmetastasis;
Discordant uptake
- MeSH:
Female;
Glucose;
Humans;
Kidney;
Lung;
Metabolism;
Middle Aged;
Neoplasm Metastasis;
Positron-Emission Tomography and Computed Tomography;
Sodium Iodide;
Sodium;
Thyroglobulin;
Thyroid Gland;
Thyroid Neoplasms;
Tomography, X-Ray Computed;
Ultrasonography;
Whole Body Imaging
- From:Nuclear Medicine and Molecular Imaging
2017;51(3):256-260
- CountryRepublic of Korea
- Language:English
-
Abstract:
Renal metastasis of thyroid cancer is extremely rare. We report the case of a 62-year-old woman with Hürthle cell thyroid cancer (HCTC) with lungs, bones, and bilateral kidneys metastases. The renal metastatic lesions were clearly demonstrated by ¹³¹I whole body scan (WBS) with SPECT/CT. However, they exhibited false-negative results in ¹⁸F-FDG PET/CT, kidney ultrasonography, and contrast-enhanced CT scan. The findings imply that tumors have low glucose metabolism and are able to accumulate radioiodine, which is not commonly found in the relatively aggressive nature of HCTC. The patient received two sessions of 200 mCi ¹³¹I therapy within 6 months duration. There was complete treatment response as evaluated by the second post-therapeutic ¹³¹I SPECT/CT and serum thyroglobulin. To our knowledge, renal metastasis from HCTC with positive ¹³¹I but negative ¹⁸F-FDGuptake has not been reported in the literature. This case suggests that ¹³¹I SPECT/CTis useful for lesion localization and prediction of ¹³¹I therapy response.
